Study of How Single Rising Doses of SAR161271 Are Absorbed and Act in Patients With Type 1 Diabetes Mellitus (T1DM)
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
- To establish initial safety/tolerability and pharmacodynamic and pharmacokinetic profiles
of four formulations of SAR161271 in patients with T1DM.
Secondary Objective:
- To establish relative potency of SAR161271 compared with insulin glargine in patients with
T1DM